Eplerenone in Metabolic Syndrome

• Research type

  Research Study

• Full title

  Eplerenone in Metabolic Syndrome: An investigation into the effects of Eplerenone on perivascular adipose tissue and small artery tone in obesity

• IRAS ID

  54728

• Contact name

  Adam Greenstein

• Sponsor organisation

  Central Manchester University Hospitals NHS Foundation Trust

• Eudract number

  2010-022308-34

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  The study is a single-centre study which aims to investigate the use of a frequently prescribed medication called Eplerenone in a condition which it is not currently licensed for. Eplerenone blocks the action of a hormone called aldosterone which is thought to damage blood vessels in obesity and cause damage (fibrosis)in the heart.For this reason we wish to see whether administration of eplerenone can improve blood vessel and adipose tissue health in obese patients30 obese patients who are generally in good health will be recruited and will undergo a procedure known as a gluteal fat biopsy. This involves removal of a small amount of skin and fat (from under the skin) under local anaesthetic. Following this, patients will take Eplerenone for 12 weeks and then will undergo a second gluteal fat biopsy. Adipose tissue and small arteries are studied from the biopsies and it is hoped that administration of the drug will result in an improvement in function. We will perform an echocardiography (heart scan) at the start and at 12 weeks after the start of medication to check for improvemends in heart function.

• REC name

  North West - Haydock Research Ethics Committee

• REC reference

  10/H1010/59

• Date of REC Opinion

  3 Dec 2010

• REC opinion

  Further Information Favourable Opinion